Sivaram P, Klein M G, Goldberg I J
Department of Medicine, Columbia University, College of Physicians and Surgeons, New York, New York 10032.
J Biol Chem. 1992 Aug 15;267(23):16517-22.
Triglycerides in circulating plasma lipoproteins are hydrolyzed by lipoprotein lipase (LPL) which is thought to bind to proteoglycans on the luminal endothelial cell surface. Previous studies from this laboratory using LPL-Sepharose affinity chromatography identified a 220-kDa LPL binding proteoglycan. Using ligand blotting with 125I-LPL, we now report a 116-kDa LPL binding protein in plasma membrane preparations of endothelial cells. 125I-LPL binding to this protein was abolished by addition of unlabeled LPL. When the cell surface of endothelial cells was labeled with biotin, a 116-kDa protein was biotinylated. Furthermore, the biotinylated 116-kDa protein bound to LPL-Sepharose and eluted with 0.4 M NaCl suggesting that the 116-kDa LPL binding protein is present on the cell surface. When detergent extracts of endothelial cells were applied to LPL-Sepharose in the presence of 0.15 M NaCl, the 116-kDa, but not the 220-kDa, protein still bound to LPL-Sepharose. The 116-kDa protein was not labeled with 35SO4 and eluted from DEAE-cellulose prior to proteoglycans, suggesting that it is not a proteoglycan. However, a 116-kDa endothelial cell surface protein was metabolically labeled with [35S]methionine. This protein was dissociated from the cell surface by incubating cells with heparin (50 units/ml)-containing buffer. After heparin treatment of endothelial cells, LPL binding to and internalization by the cells decreased greater than 70% compared to control cells. These results suggest that endothelial cells synthesize a heparin-releasable, high affinity 116-kDa LPL binding protein. We postulate that this protein is associated with proteoglycans on luminal endothelial surfaces and mediates LPL binding, internalization, and recycling. We name this protein hrp (heparin-releasable protein)-116.
循环血浆脂蛋白中的甘油三酯被脂蛋白脂肪酶(LPL)水解,该酶被认为与腔面内皮细胞表面的蛋白聚糖结合。本实验室先前使用LPL - 琼脂糖亲和色谱法的研究鉴定出一种220 kDa的LPL结合蛋白聚糖。现在我们使用125I - LPL进行配体印迹分析,在内皮细胞质膜制剂中发现了一种116 kDa的LPL结合蛋白。添加未标记的LPL可消除125I - LPL与该蛋白的结合。当用生物素标记内皮细胞表面时,一种116 kDa的蛋白被生物素化。此外,生物素化的116 kDa蛋白与LPL - 琼脂糖结合,并用0.4 M NaCl洗脱,这表明116 kDa的LPL结合蛋白存在于细胞表面。当在内皮细胞的去污剂提取物中加入0.15 M NaCl并应用于LPL - 琼脂糖时,116 kDa的蛋白(而非220 kDa的蛋白)仍与LPL - 琼脂糖结合。116 kDa的蛋白未被35SO4标记,且在蛋白聚糖之前从DEAE - 纤维素上洗脱,这表明它不是蛋白聚糖。然而,一种116 kDa的内皮细胞表面蛋白被[35S]甲硫氨酸代谢标记。通过用含肝素(50单位/毫升)的缓冲液孵育细胞,该蛋白从细胞表面解离。与对照细胞相比,用肝素处理内皮细胞后,LPL与细胞的结合及内化减少了70%以上。这些结果表明内皮细胞合成一种可被肝素释放的、高亲和力的116 kDa LPL结合蛋白。我们推测该蛋白与腔面内皮表面的蛋白聚糖相关,并介导LPL的结合、内化和循环利用。我们将这种蛋白命名为hrp(肝素可释放蛋白)- 116。